Phase II Trial of Chemotherapy with Docetaxel plus Cisplatin for Patients with Recurrent or Metastatic Non-squamous Cell Carcinoma of Head and Neck
Latest Information Update: 28 Sep 2021
Price :
$35 *
At a glance
- Drugs Cisplatin (Primary) ; Docetaxel (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- Acronyms HN non-SCC P2 DC
- 17 Nov 2017 Status changed from active, no longer recruiting to completed.
- 05 Jan 2017 Planned End Date changed from 1 Sep 2015 to 1 Nov 2017.
- 05 Jan 2017 Status changed from recruiting to active, no longer recruiting.